Press Releases

NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it is expanding its CD33 program studying Actimab-A into a combination trial with the chemotherapy regimen 7+3 in patients with newly diagnosed acute myeloid leukemia (AML) who have intermediate or high-risk cytogenetic or molec

CUPERTINO, Calif., Feb. 26, 2020 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results and host a conference call after the market close on Tuesday, March 3, 2020.

CHICAGO, Feb. 26, 2020 /PRNewswire/ -- Third Eye Health, the nation's largest post-acute telehealth provider, announced today that its solution has been integrated with

TARRYTOWN, N.Y., Feb. 26, 2020 /PRNewswire/ -- Recognizing the growing importance of quality behavioral health programs for payers, The IMA Group (IMA) announced today the acquisition of P

VANCOUVER, Feb. 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its financial results for 2019 will be released

CAMBRIDGE, Mass., Feb. 26, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, Douglas E. Onsi, Chief Financi

CARLSBAD, Calif., Feb. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter and full year 2019 and recent business highlights.

CHICAGO, Feb. 26, 2020 /PRNewswire/ -- Hillrom (NYSE: HRC) announced today that its board of directors declared a 5 percent increase in the company's quarterly dividend rate, from the previous rate of $0.21 per share to $0.22 per share. The fiscal second quarter 2020 quarterly dividend is payable on March 31, 2020, to shareholders of r

NEW YORK, Feb. 26, 2020 /PRNewswire/ -- The promise and potential risks of machine learning and other technology will be examined by experts at the 29th Healthcare Risk Management / Patient Safety Conference on Wednesday, March 11, at the New York Marriott Marquis.

DENVER, Feb. 26, 2020 /PRNewswire/ -- DaVita Kidney Care